Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum

Woltering, Eugene A.; Beyer, David T.; Thiagarajan, Ramcharan; Ramirez, Robert A.; Wang, Yi-Zarn; Ricks, M. Jennifer; Boudreaux, J. Philip

doi:10.1016/j.jamcollsurg.2015.12.014

Cited by 12 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 Pancreastatin, a breakdown product of CgA, may be more specific in certain contexts, such as patients using proton pump inhibitors (which raise CgA levels). 39,40 …”

Section: Resultsmentioning

confidence: 99%

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

Strosberg¹,

Halfdanarson²,

Bellizzi³

et al. 2017

Pancreas

260

203

View full text Add to dashboard Cite

There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors. Key phase III studies include the CLARINET trial which evaluated lanreotide in patients with non-functioning enteropancreatic NETs, the RADIANT 2 and RADIANT 4 studies, which evaluated everolimus in functioning and non-functioning NETs of the GI tract and lungs, the TELESTAR study which evaluated telotristat ethyl in patients with refractory carcinoid syndrome, and the NETTER-1 trial which evaluated 177Lutetium-dotatate in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society (NANETS) convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and post-operative surveillance) are summarized in this manuscript. Surgical guidelines are described in a companion manuscript.

show abstract

“…38 Pancreastatin, a breakdown product of CgA, may be more specific in certain contexts, such as patients using proton pump inhibitors (which raise CgA levels). 39,40 …”

Section: Resultsmentioning

confidence: 99%

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

Strosberg¹,

Halfdanarson²,

Bellizzi³

et al. 2017

Pancreas

260

203

View full text Add to dashboard Cite

show abstract

“…Duodenal NETs comprise 2-3% of all gastrointestinal (GI) endocrine tumors [ 1 ]. Although rare, multiple reports cite an increasing incidence of duodenal NETs, with one publication reporting a 400% increase from 1983 to 2010 [ 3 ]. This increase might be due to a raised awareness by physicians and a greater frequency of routine endoscopic surveillance.…”

Section: Discussionmentioning

confidence: 99%

“…The five-year survival for duodenal carcinoid lesions is 60% [ 5 ]. Some studies have demonstrated the efficacy of plasma pancreastatin and chromogranin A as a predictor of overall survival for primary duodenal NETs [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

A Rare Location of a Neuroendocrine Tumor

Chaaya¹,

Vásquez

Zayat

2016

Cureus

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) arising in the duodenum are rare neoplasms that are often classified as indolent and have a low potential to metastasize. Although rare, multiple reports cite an increasing incidence of duodenal NETs. Symptoms are usually nonspecific and the diagnosis is made via endoscopy. Endoscopic resection is the mainstay of therapy. The prognosis is usually favorable. We describe a case of a duodenal NET that presented with vague symptoms in order to increase the awareness of this rare but increasing in frequency entity.

show abstract

“…Arresse et al also reported that a 20% or greater decrease in serum pancreastatin corresponded to prolonged overall survival [ 22 ]. Earlier studies had concluded that there was an association between serum pancreastatin and overall survival in patients with NELM [ 32 , 33 ]; Strosberg and Arresse confirmed that the association held true after locoregional therapy (TACE). Strosberg et al suggest that serum pancreastatin can be monitored in addition to radiographic assessment to assess treatment response and disease progression [ 1 ].…”

Section: Reviewmentioning

confidence: 97%

A Comparison of the Outcomes of Transarterial Chemoembolization and Transarterial Radioembolization in the Management of Neuroendocrine Liver Metastases in Adults: A Systematic Review

Srinivasan¹,

Venugopal²

2023

Cureus

View full text Add to dashboard Cite

The purpose of this article is to review the existing English scientific literature and determine the superior modality between transarterial chemoembolization (TACE) and radioembolization (TARE) in the treatment of neuroendocrine liver metastases (NELMs). To that end, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to search PubMed, the Cochrane Library, and Google Scholar. We identified 14 observational studies and no randomized controlled trials (RCTs) investigating the use of TACE or TARE to treat NELM. We used the Newcastle-Ottawa Scale to assess the risk of bias in these studies. We concluded that TACE and TARE appeared to have similar outcomes when comparing overall survival, progression-free survival, radiological response, symptomatic response, and the incidence of severe adverse events. Further large-scale RCTs are needed to identify the superior modality conclusively. We also identified several unique prognostic factors for overall survival, such as the neutrophillymphocyte ratio, volumetric multiparametric magnetic resonance imaging, serum albumin, alkaline phosphatase, and pancreastatin.

show abstract

Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum

Cited by 12 publications

References 15 publications

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

A Rare Location of a Neuroendocrine Tumor

A Comparison of the Outcomes of Transarterial Chemoembolization and Transarterial Radioembolization in the Management of Neuroendocrine Liver Metastases in Adults: A Systematic Review

Contact Info

Product

Resources

About